Clinical Trial: A Phase II Study of SSGJ-612 Plus a HER2-Targeted ADC in HR-Positive, HER2-Low or HER2-Ultralow Expression Metastatic Breast Cancer

U.S., Aug. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07757230) titled 'A Phase II Study of SSGJ-612 Plus a HER2-Targeted ADC in HR-Positive, HER2-Low or HER2-Ultralow Expression Metastatic Breast Cancer' on Aug. 06.

Brief Summary: This study is a phase II clinical trial of SSGJ-612 combined with a human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate (ADC) in patients with hormone receptor (HR)-positive, HER2-low or HER2-ultralow metastatic breast cancer.

Study Start Date: Sept., 2026

Study Type: INTERVENTIONAL

Condition: Metastatic Breast Cancer

Intervention: DRUG: SSGJ-612 (HER2-targeted antibody)

Intravenous injection

DRUG: HER2-targeted ADC

Intravenous injection...